Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaven I&g 4 Regulatory News (MAV4)

Share Price Information for Maven I&g 4 (MAV4)

Share Price is delayed by 15 minutes
Get Live Data
50.00    0.00 (0.00%)
Bid:
49.00
Ask:
51.00
Spread: 2.00 (4.082%)
Market Cap: £83.71m
MAV4 Live PriceLast checked at - London Stock Exchange

Intraday Maven I&g 4 Share Chart

Merger Results

3 Apr 2013 13:54

RNS Number : 4828B
Maven Income & Growth VCT 4 PLC
03 April 2013
 

Maven Income & Growth VCT 4 plc ("Company")

 

Merger Results

 

3 April 2013

 

This announcement is made by Maven Income & Growth VCT 4 plc ("the Company") in connection with the merger of the Company with Ortus VCT PLC ("Ortus") to be completed by way of a scheme of reconstruction of Ortus pursuant to Section 110 of the Insolvency Act 1986 and the transfer by Ortus of all of its assets and liabilities to the Company ("Scheme"), details of which were contained in the Company's circular to shareholders ("the Circular") and the Company's prospectus ("the Prospectus"), both dated 1 March 2013.

 

The board is pleased to advise that the resolution proposed at the general meeting of Ortus held today was duly passed to be able to implement and effect the Scheme.

 

By way of implementation of the Scheme, the assets and liabilities of Ortus have been transferred to the Company in consideration for the issue of new ordinary shares of 10p each ("Ordinary Shares") and new C ordinary shares of 10p each ("C Shares"), in each case in the capital of the Company as set out below.

 

The total number of new Ordinary Shares issued to Ortus shareholders in connection with the Scheme was 6,853,086 at a deemed issue price of 94.24p per share and the total number of new C Shares issued to Ortus shareholders in connection with the Scheme was 3,968,876 at a deemed issue price of £1.00 per share.

 

Following implementation of the Scheme, there are now 22,078,966 Ordinary Shares and 3,968,876 C Shares in issue in the Company. Therefore, the total number of voting rights in the Company is 26,047,842, which may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or change to their interest in, the Company under the FSA's Disclosure and Transparency Rules.

 

Application has been made for all of the new shares issued pursuant to the Scheme to be admitted to the Official List and to trading on the main market of the London Stock Exchange. It is expected that admission will become effective and that trading will commence on 4 April 2013. CREST accounts are also expected to be credited on 4 April 2013.

 

An allotment in respect of applications received pursuant to the Company's offer for subscription is expected to take place on 5 April 2013 for the 2012/2013 tax year.

 

For further enquiries please contact:

 

Maven Capital Partners UK LLP

0141 306 7400

enquiries@mavencp.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCKMGGDZFFGFZM
Date   Source Headline
20th May 202610:12 amRNSAdmission of Further Securities to Trading
15th May 202610:45 amRNSDirector/PDMR Shareholding
15th May 202610:41 amRNSIssue of Equity - Dividend Investment Scheme
14th May 20265:22 pmRNSTransaction in Own Shares
12th May 20263:37 pmRNSUnaudited NAV - Dividend Investment Scheme
7th May 20261:45 pmRNSResult of AGM
30th Apr 202610:58 amRNSAdmission of Further Securities to Trading
29th Apr 202612:29 pmRNSIssue of Equity
20th Apr 202612:23 pmRNSPublication of a Supplementary Prospectus
15th Apr 202611:27 amRNSAdmission of Further Securities to Trading
14th Apr 202611:09 amRNSIssue of Equity
10th Apr 202612:02 pmRNSUnaudited Net Asset Value
8th Apr 20269:33 amRNSAdmission of Further Securities to Trading
25th Mar 20263:51 pmRNSTransaction in Own Shares
25th Mar 202610:55 amRNSAdmission of Further Securities to Trading
24th Mar 202612:11 pmRNSIssue of Equity
19th Mar 20264:21 pmRNSUnaudited NAV and Proposed Final Dividend
18th Feb 20264:58 pmRNSAdmission of Further Securities to Trading
17th Feb 202611:07 amRNSDirector/PDMR Shareholding
17th Feb 202611:07 amRNSDirector/PDMR Shareholding
17th Feb 202610:54 amRNSIssue of Equity
4th Feb 20267:00 amRNSStatement re Offer for Subscription
21st Jan 202611:07 amRNSAdmission of Further Securities to Trading
20th Jan 20262:05 pmRNSAdmission of Further Securities to Trading
16th Jan 20269:52 amRNSDirector/PDMR Shareholding
16th Jan 20269:44 amRNSIssue of Equity
15th Jan 202610:36 amRNSDirector/PDMR Shareholding
15th Jan 202610:35 amRNSDirector/PDMR Shareholding
15th Jan 20269:55 amRNSIssue of Equity
14th Jan 20262:39 pmRNSUnaudited NAV - Dividend Investment Scheme
13th Jan 202612:10 pmRNSUnaudited Net Asset Value
4th Dec 202510:35 amRNSSecond Interim Dividend
18th Nov 20253:48 pmRNSTransaction in Own Shares
14th Nov 20259:31 amRNSNet Asset Value(s)
13th Nov 20254:53 pmRNSResult of General Meeting
2nd Oct 20254:42 pmRNSPublication of a Prospectus
29th Aug 20257:00 amRNSDirector/PDMR Shareholding
29th Aug 20257:00 amRNSIssue of Equity
29th Aug 20257:00 amRNSHalf-year Report
20th Aug 20252:14 pmRNSStatement re Dividend Investment Scheme
31st Jul 20254:42 pmRNSTransaction in Own Shares
16th Jul 202510:18 amRNSStatement re Unaudited NAV and Interim Dividend
16th Jul 20257:08 amRNSStatement re Offer for Subscription
21st May 20254:44 pmRNSTransaction in Own Shares
16th May 20259:30 amRNSDirector/PDMR Shareholding
16th May 20259:26 amRNSIssue of Equity - Dividend Investment Scheme
9th May 20251:53 pmRNSStatement re Dividend Investment Scheme
9th May 202510:03 amRNSNet Asset Value(s)
8th May 20251:43 pmRNSResult of AGM
6th May 202511:55 amRNSIssue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.